Pre-transplant Serum Beta-2 Microglobulin Level is a Potential Novel Prognostic Marker of Overall Survival after Allogeneic Hematopoietic Cell Transplantation- a retrospective observational study.
Although elevated serum beta-2 microglobulin (BMG) has been reported as a poor prognostic marker for various hematological malignancies, no study has assessed its prognostic significance in allogenic hematopoietic cell transplantation (allo-HCT). Therefore, we conducted this retrospective observational study in 227 consecutive patients with available pre-transplant serum BMG levels between April 2010 and September 2017 at our institute. We also collected and retrospectively analyzed various pre-transplant variables likely related to transplant outcomes. Multivariable analysis, including major prognostic variables, such as the disease risk index and the hematopoietic cell transplant-comorbidity index, showed a significant association between higher serum BMG levels and poorer overall survival (OS) in all three adjusted models (hazard ratio [HR] per its standard deviation (SD) (SD=1.094): 1.67 (1.35-2.03) [p<0.001], HR per SD: 1.46 (1.14-1.86) [p=0.002], HR per SD: 2.03 (1.62-2.55) [p<0.001], respectively, due to the significant association between higher serum BMG levels and relapse/progression (HR 1.52 (1.20-1.94) [p<0.001]) instead of non-relapse mortality (HR 1.06 (0.70-1.60) [p=0.780]). Moreover, DRI and serum BMG had statistically significantly higher c-statistic estimates for OS compared with DRI alone. (c-index 0.74 and 0.68, respectively; p<0.001) In conclusion, pre-transplant serum BMG level may serve as a useful prognostic marker and help clinical decision in allo-HCT.